Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, G.-Y. | - |
dc.contributor.author | Jung, S.-H. | - |
dc.contributor.author | Lee, J.-J. | - |
dc.contributor.author | Kim, J.S. | - |
dc.contributor.author | Min, C.-K. | - |
dc.contributor.author | Kim, K. | - |
dc.contributor.author | Choi, Y. | - |
dc.contributor.author | Eom, H.-S. | - |
dc.contributor.author | Joo, Y.D. | - |
dc.contributor.author | Kim, S.-H. | - |
dc.contributor.author | Kwak, J.-Y. | - |
dc.contributor.author | Kang, H.J. | - |
dc.contributor.author | Lee, J.H. | - |
dc.contributor.author | Lee, H.S. | - |
dc.contributor.author | Mun, Y.-C. | - |
dc.contributor.author | Moon, J.H. | - |
dc.contributor.author | Sohn, S.K. | - |
dc.contributor.author | Park, S.K. | - |
dc.contributor.author | Park, Y. | - |
dc.contributor.author | Shin, H.-J. | - |
dc.contributor.author | Yoon, S.-S. | - |
dc.date.available | 2020-12-02T01:40:21Z | - |
dc.date.created | 2020-07-13 | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 1042-8194 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79167 | - |
dc.description.abstract | We compared the efficacy and toxicity of busulfan and melphalan (BUMEL) and those of high-dose melphalan (HDMEL) as conditioning regimens for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) through a propensity score-matched analysis. No significant difference in the complete response and overall response rate after ASCT was observed between BUMEL and HDMEL. After a median follow-up of 37.3 months in the BUMEL group and 50.8 months in the HDMEL group, the median progression-free survival was calculated to be 32.9 months and 25.2 months (p = 0.995). With respect to non-hematologic toxicities, infections were more frequently reported in the BUMEL group (p < 0.001). Three patients who received BUMEL developed veno-occlusive disease (VOD), and all of them recovered without administration of defibrotide. In conclusion, BUMEL is an effective alternative conditioning regimen in terms of efficacy, but attention should be paid to toxicities. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Taylor and Francis Ltd | - |
dc.relation.isPartOf | Leukemia and Lymphoma | - |
dc.title | Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000547986700001 | - |
dc.identifier.doi | 10.1080/10428194.2020.1783448 | - |
dc.identifier.bibliographicCitation | Leukemia and Lymphoma, v.61, no.11, pp.2714 - 2721 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85087449806 | - |
dc.citation.endPage | 2721 | - |
dc.citation.startPage | 2714 | - |
dc.citation.title | Leukemia and Lymphoma | - |
dc.citation.volume | 61 | - |
dc.citation.number | 11 | - |
dc.contributor.affiliatedAuthor | Lee, J.H. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | autologous stem cell transplantation | - |
dc.subject.keywordAuthor | conditioning regimen | - |
dc.subject.keywordAuthor | Multiple myeloma | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.